anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: Sleeve gastrectomy (SG) is a widely used and effective treatment for patients with obesity and comorbid metabolic abnormalities. No specialized tool is available to predict metabolic syndrome (MS) remission after SG. We presented a nomogram that evaluated the probability of MS remission in obese patients 1 year after SG.
MATERIALS AND METHODS: Patients with preoperative MS who underwent SG were enrolled in this retrospective study. They were divided into a training set and a validation set. Multivariate logistic regression analysis was performed to identify independent predictors of MS remission, and these predictors were included in the nomogram. Receiver operating characteristic curve was used to evaluate discrimination. Calibration was performed with the Hosmer-Lemeshow goodness-of-fit test. The net benefits of the nomogram were evaluated using decision curve analysis (DCA).
RESULTS: Three hundred and eighteen patients with a median age of 34.0 years were analyzed. A training set and a validation set with 159 individuals each were established. A combination of age, preoperative high-density lipoprotein cholesterol, elevated triglycerides and glycated hemoglobin level independently and accurately predicted MS remission. The nomogram included these factors. The discriminative ability was moderate in training and validation sets (Area under curve 0.800 and 0.727, respectively). The Hosmer-Lemeshow X2 value of the nomogram was 8.477 (P = 0.388) for the training set and 5.361 (P = 0.718) for the validation set, indicating good calibration. DCA showed the nomogram had clinical benefits in both datasets.
CONCLUSION: Our nomogram could accurately predict MS remission in Chinese patients with obesity 1 year after SG.
The present invention relates to a method for extracting antibiotic materials from licorice and licorice extracts obtained by the method for cavity prevention. A dried licorice root powder is digested in a mixed solution of ethanol and butanol to extract active ingredients. These active ingredients are then filtered and the solvent is removed from the filtered extract solution. The extract solution free of the solvent is dissolved in methanol, and extracted repeatedly with ethyl acetate to remove the solvent again. The ethyl acetate extract free of the solvent is dissolved in methanol, and extracted repeatedly with n-hexane to remove the extract. Next, 50 vol% of water is added to the residual methanol layer, and the resulting mixed solution is extracted with chloroform, separated on a silica gel column to obtain fractions. The reaction is checked by TLC, and fractions having similar RF values are combined and categorized into 8 fractions. Later, an antimicrobial test is carried, and 2 fractions with excellent antimicrobial properties are obtained. This antimicrobial material derived from licorice is then mixed with an anti-cavity composition for the prevention and treatment of cavities.
A pre-implantation ECG mapping with the Amycard 01C device, including CT, is performed prior to the CRT device implantation. The resulting target area for the left ventricular lead placement is communicated to the implanting physician, who will attempt to reach a point close to the target, using the available venous access. At six-month follow-up, response to the therapy is assessed using echocardiography, and a second ECG mapping with Amycard 01C is performed, to assess the distance between actual implantation site and target in the presence of pre-implantation planning information.
In cycle I of the study, participants will be randomized on to flexible-dose VTX (10-20 mg) versus. Vortioxetine starting dose will be 10 mg daily. Vortioxetine starting dose will be 10 mg daily with a dose escalation up to 20 mg daily at week #4. Study cycle II is an 8-week, open label treatment design for non-responders completing the Cycle I RCT. One treatment arm will continue VTX non-responders to 8 week VTX (10-20 mg/day) augmentation with cognitive behavioral therapy (10 sessions). The 2nd treatment arm will continue placebo non-responders who complete the RCT to VTX (10 to 20 mg/day). The third treatment arm will continue VTX responders/remitters who complete the RCT to open-label VTX for another 8-weeks to assess maintenance efficacy for up to 16 weeks.
PCT No. PCT/NL93/00163 Sec. 371 Date May 1, 1995 Sec. 102(e) Date May 1, 1995 PCT Filed Jul. 30, 1993 PCT Pub. No. WO94/08021 PCT Pub. Date Apr. 14, 1994The invention is directed to an immunity providing B cell activating molecule derived from a meningococcal lipopolysaccharide (LPS) having at least one epitope, said molecule comprising at least the communal part of the oligosaccharide part (core region) of lipopolysaccharides specific for at least two meningococcal immunotypes, preferably immunotypes L2 and L3 and wherein in galactose is absent in the B cell activating part, as well as derivatives of the molecules with immuno reaction inducing capacity. The invention is also directed at an outer membrane vesicle provided with a group of polypeptides having at least the immunoactivity of outer membrane proteins (OMP's) bound to a membrane, a polypeptide from the group of said outer membrane vesicles being a membrane anchored OMP or OMP fragment with a mutation in one of the surface loops, preferably in a 2, 3, 5, 6, 7 or 8-loop of a class I OMP. Furthermore, the invention is directed at a vaccine comprising such an outer membrane vesicle and/or lipopolysaccharide, as well as methods for preparing a lipopolysaccharide and an outer membrane vesicle as described above.
Participants will receive standard medical therapy along with the empiric strategy of treatment of invasive fungal infection (based on both risk factors and clinical suspicion of invasive fungal infection). The choice of drug will be as per institutional protocol i.e. Injection Liposomal Amphotericin B, 3-5 mg/kg of body weight as a 4- hour infusion in 5% dextrose solution. The infusion will be prepared ten minutes prior to administration by reconstituting the vial in dextrose solution by a Registered Nurse. Each vial contains 50 mg (50000U) encapsulated in liposomes. After reconstitution, the concentrate will contain 4mg/ml of the drug. During the first dose administration, 1mg will be administered with a micro drip set over ten minutes and then stopped to look for any reactions for 30 minutes. If there are no reactions, the rest of the drug is administered over 30-60 minutes period.
Cleviprex was evaluated in a randomized, placebo-controlled, single-blind, parallel 72-hour continuous infusion study in 61 mild to moderate essential hypertensives. The mean baseline blood pressure was 151/86 mmHg.

Subjects were randomized to placebo or to 2, 4, 8, or 16 mg/hour. Doses above 2 mg/hour were started at 2 mg/hour and force-titrated in 2-fold increments at 3-minute intervals. Blood pressure, heart rate, and blood levels of clevidipine were measured during the infusion period. Blood levels were monitored 1 hour after the infusion was discontinued. Blood pressure and heart rate were monitored for 8 hours and also at 96 hours after the termination of infusion. Systolic blood pressure effect was related to the concentration of clevidipine and plateaued at higher measured concentrations, with the maximal effect estimated at 25% of baseline systolic blood pressure. The estimated infusion rate necessary to achieve half of this maximal effect was approximately 10 mg/hour.
The invention described herein relates to a therapeutic, moisturizing coating composition for elastomeric articles which is applied directly onto the skin-contacting surface of the article as part of the manufacturing process. The coating composition is thermally stable and subsequently transfers when in contact with a skin surface to convert into a liquid "lotion" form during wearing of the article. The coating composition provides therapeutic benefits to the wearer's skin as a result of wearing the article, such as improved skin moisturization, softness of feel, improved skin elasticity and firmness, and reduced redness and irritation. The invention is particularly useful in medical gloves, including examination and surgical gloves. The coating composition comprises about 10% to about 95% w/w of a transferable moisturizer. The therapeutic coating composition is transferable upon contact with skin and comprises less than 1.0% water by weight of the composition.
Pseudo – parkinsonism: Symptoms may include: mask-like facies, drooling, tremors, pillrolling motion, cogwheel rigidity and shuffling gait. In most cases these symptoms are readily controlled when an anti–parkinsonism agent is administered concomitantly. Anti–parkinsonism agents should be used only when required. Generally, therapy of a few weeks to 2 or 3 months will suffice. After this time patients should be evaluated to determine their need for continued treatment. (Note: Levodopa has not been found effective in antipsychotic–induced pseudo–parkinsonism.) Occasionally, it is necessary to lower the dosage of chlorpromazine or to discontinue the drug.
Clofarabine 2 mg for 21 days followed by 7 days of rest. Each cycle is 28 days long.
Provided are a machine learning-based autism spectrum disorder (ASD) diagnosis method and device using a metabolite as a marker. The method comprises: measuring the content of at least one marker in a sample of a subject and comparing same with the content of the corresponding marker in a healthy control, or using an algorithm constructed by machine learning to process the content of the marker. Particularly, the marker is a metabolite in human urine. The device comprises: an accommodation space, configured to place the sample of the subject; a testing unit, configured to test the marker in the sample to obtain the content of the marker; and a calculation and determination unit, configured to perform calculation on the basis of the content of the marker according to a predetermined algorithm to obtain an indication of whether the subject suffers from ASD. According to the present application, the change pattern of a metabolite in urine is mined by means of a machine learning algorithm to provide diagnoses for children suffering from ASD. The device based on a predetermined algorithm provided by the present application can provide a new strategy for diagnosis of ASD.
The invention concerns the combined use of chemokine IP-10 and interleukin 12 as therapy against malignant tumors and the use of IP-10 to potentiate the anti-tumoral effect of IL-12. Said substances are immunomodulating proteins enhancing anti-tumoral response. Combined administration of both substances to mammals makes it possible to enhance anti-tumoral activity in the tumor carrying mammal. Administration of both substances can be realized by means of a recombinant protein prepared in-vitro or by means of expression systems or gene transfer expressing said substances. The combination of both substances has a synergistic effect in the specific induction of cytotoxic lymphocytes against tumors. Combination of both substances in adequate proportions and dose can be useful in the treatment of any type of cancer, for instance adenocarcinoma of the colon.
Women suggested endometriosis by clinical presentations \& imaging and scheduled for surgical treatment (laparotomy/laparoscopy) at the age of 18-45 years having regular menstrual cycles will be recruited. Finally laparoscopy and histology confirmed endometriosis cases will be eligible for the final analysis.
Subjects diagnosed with Mild Autonomous Cortisol Secretion (MACS) will receive metyrapone for a 6 month treatment period (Open Label Phase) with the option to continue for an additional 30 months of metyrapone therapy. If a patient chooses to participate in the Optional Extension Phase they will continue to receive metyrapone therapy until Month 36. This is an additional 30 months of therapy after completion of the Open Label Phase.
INTRODUCTION: Differential diagnosis among subjects with Primary Progressive Aphasia (PPA) can be challenging. Structural MRI can support the clinical profile. Visual rating scales are a simple and reliable tool to assess brain atrophy in the clinical setting. The aims of the study were to establish to what extent the visual rating scales could be useful in the differential diagnosis of PPA, to compare the clinical diagnostic impressions derived from routine MRI interpretations with those obtained using the visual rating scale and to correlate results of the scales in a voxel-based morphometry (VBM) analysis.
METHOD: Patients diagnosed with primary progressive aphasia (PPA) according to current criteria from two centers-Ospedale Maggiore Policlinico of Milan and Hospital Clínic de Barcelona-were included in the study. Two blinded clinicians evaluated the subjects MRIs for cortical atrophy and white matter hyperintensities using two protocols: routine readings and the visual rating scale. The diagnostic accuracy between patients and controls and within PPA subgroups were compared between the two protocols.
RESULTS: One hundred fifty Subjects were studied. All the scales showed a good to excellent intra and inter-rater agreement. The left anterior temporal scale could differentiate between semantic PPA and all other variants. The rater impression after the protocol can increase the accuracy just for the logopenic PPA. In the VBM analysis, the scores of visual rating scales correlate with the corresponding area of brain atrophy.
CONCLUSION: The Left anterior temporal rating scale can distinguish semantic PPA from other variants. The rater impression after structured view improved the diagnostic accuracy of logopenic PPA compared to normal readings. The unstructured view of the MRI was reliable for identifying semantic PPA and controls. Neither the structured nor the unstructured view could identify the nonfluent and undetermined variants.
Irregular cycles (under 21 days or more than 35 days). Contraceptives use of any type (Hormonal intervention).
The invention relates to a prescription for treating intractable stomach troubles. The prescription comprises 15g of Chinese thorowax root, 15g of Wenchow turmeric root tuber, 10g of tangerine peel, 10g of ternate pinellia, 20g of white peony root, 3g of officinal magnolia bark, 15g of hematite, 15g of cuttlefish, 15g of submature bitter orange, 15g of salvia miltiorrhiza, 15g of jujube kernel, 15g of corydalis tuber, 20g of dandelion, 10g of rhubarb, and 10g of licorice root. The components are decocted by using water, and the obtained liquid is taken. Or, approximately 1500ml of water can be added; the components are decocted 3 times; filtering is carried out, and the liquid is obtained; and the liquid is bottled and is subjected to high-temperature sterilization, such that the product can be preserved for later use. The prescription provides substantial calming, sedative, and analgesic effects for central nervous systems. The prescription has the functions of liver soothing, qi regulating, stomach regulating, adverse-rising energy calming, vomiting stopping, stomach emptying promoting, and gastrointestinal movement promoting. The prescription also provides anti-inflammatory and absorption promotion effects against mucosal inflammation and hyperplasia. The prescription also has a helicobacter pylori elimination function. The prescription is provided on a basis of a combination of traditional Chinese medical science and western medical science. With the prescription, both symptoms and causes can be treated, and optimal effects are provided for eliminating symptoms such as swelling, pain, belching, and discomfort. Also, a psychological regulation effect is provided. As a result of years of applications, the prescription has a good effect.
This Thoracic Society of Australia and New Zealand Guideline on the provision of home oxygen therapy in adults updates a previous Guideline from 2015. The Guideline is based upon a systematic review and meta-analysis of literature to September 2022 and the strength of recommendations is based on GRADE methodology. Long-term oxygen therapy (LTOT) is recommended for its mortality benefit for patients with COPD and other chronic respiratory diseases who have consistent evidence of significant hypoxaemia at rest (PaO2 ≤ 55 mm Hg or PaO2 ≤59 mm Hg in the presence of hypoxaemic sequalae) while in a stable state. Evidence does not support the use of LTOT for patients with COPD who have moderate hypoxaemia or isolated nocturnal hypoxaemia. In the absence of hypoxaemia, there is no evidence that oxygen provides greater palliation of breathlessness than air. Evidence does not support the use of supplemental oxygen therapy during pulmonary rehabilitation in those with COPD and exertional desaturation but normal resting arterial blood gases. Both positive and negative effects of LTOT have been described, including on quality of life. Education about how and when to use oxygen therapy in order to maximize its benefits, including the use of different delivery devices, expectations and limitations of therapy and information about hazards and risks associated with its use are key when embarking upon this treatment.
Cohort 1: HSK3486 0.324 mg/kg + etomidate 0.15 mg/kg Cohort 2: HSK3486 0.216 mg/kg + etomidate 0.2 mg/kg Cohort 3: HSK3486 0.432 mg/kg + etomidate 0.1 mg/kg There were an additional 2 cohorts (Cohorts 4 and 5) planned for dose escalation once the optimal ratio of the drug combination was identified from the first 3 cohorts. However, these 2 cohorts were not done as the results of Cohorts 1 to 3 suggested that dose increases would cause higher occurrence of drug-related adverse events (AEs).
In the apnoeic oxygenation group the HFNO is used for pre-oxygenation,100 % O2, 40 L/min during 3 min. Thereafter, anaesthesia is induced by intravenous Propofol and Remifentanil. Rocuronium for full neuromuscular blockade is administered and a jaw thrust is used to keep an open airway. The airway will be kept patent throughout the procedure using a suspension laryngoscope, placed by the ENT surgeon. During apnoea oxygen will be increased to 70 L/min, 100% O2. Apnoea will be discontinued if any of the criteria SpO2 \< 90%, PaCO2 \>11 kPa, pH \<7.15 or arrhythmias with haemodynamic effects occur.
BACKGROUND AND OBJECTIVES: Previously we demonstrated that 90% of infarcts in children with sickle cell anemia occur in the border zone regions of cerebral blood flow (CBF). We tested the hypothesis that adults with sickle cell disease (SCD) have silent cerebral infarcts (SCIs) in the border zone regions, with a secondary hypothesis that older age and traditional stroke risk factors would be associated with infarct occurrence in regions outside the border zones.
METHODS: Adults with SCD 18-50 years of age were enrolled in a cross-sectional study at 2 centers and completed a 3T brain MRI. Participants with a history of overt stroke were excluded. Infarct masks were manually delineated on T2-fluid-attenuated inversion-recovery MRI and registered to the Montreal Neurological Institute 152 brain atlas to generate an infarct heatmap. Border zone regions between anterior, middle, and posterior cerebral arteries (ACA, MCA, and PCA) were quantified using the Digital 3D Brain MRI Arterial Territories Atlas, and logistic regression was applied to identify relationships between infarct distribution, demographics, and stroke risk factors.
RESULTS: Of 113 participants with SCD (median age 26.1 years, interquartile range [IQR] 21.6-31.4 years, 51% male), 56 (49.6%) had SCIs. Participants had a median of 5.5 infarcts (IQR 3.2-13.8). Analysis of infarct distribution showed that 350 of 644 infarcts (54.3%) were in 4 border zones of CBF and 294 (45.6%) were in non-border zone territories. More than 90% of infarcts were in 3 regions: the non-border zone ACA and MCA territories and the ACA-MCA border zone. Logistic regression showed that older participants have an increased chance of infarcts in the MCA territory (odds ratio [OR] 1.08; 95% CI 1.03-1.13; p = 0.001) and a decreased chance of infarcts in the ACA-MCA border zone (OR 0.94; 95% CI 0.90-0.97; p < 0.001). The presence of at least 1 stroke risk factor did not predict SCI location in any model.
DISCUSSION: When compared with children with SCD, in adults with SCD, older age is associated with expanded zones of tissue infarction that stretch beyond the traditional border zones of CBF, with more than 45% of infarcts in non-border zone regions.
Phase 1, open-label, non-randomized, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of HBI-8000 administered orally. Patients must be hospitalized as per guidance of the treating investigator throughout Cycle 1. Patients will receive HBI 8000 twice weekly (BIW) (after breakfast), in 28 day treatment cycles.

Patients will be enrolled in cohorts of 3 patients. The first cohort of 3 patients will receive 30 mg BIW. Decisions regarding cohort escalation will be based upon the clinical experience in Cycle 1 (first 28 days) only. For a given cohort, if 1 patient enrolled in the cohort experiences a dose limiting toxicity (DLT) within 28 days of the first dose, the cohort will be expanded to 6 patients.
PURPOSE:To provide the titled ointment by compounding zinc chloride as the drug component, with zinc oxide powder, red oxide, sulfur powder, and castor oil at proper ratios, wherein the amount of the zinc chloride is adjusted according to the use. CONSTITUTION:The stock solution of zinc chloride is heated taking care of keeping the liquid from excessively high temperature, and the water is completely evaporated to leave white zinc chloride powder (i). The powder is added with castor oil, and stirred thoroughly to obtain a white cream (ii). Zinc oxide powder is ground in a mortar until the powder becomes extremely fine powder, and added to (ii) and stirred (iii). Finally, red oxide and sulfur powder are ground in a mortar until the mixture becomes fine powder, added to (iii), and kneaded thoroughly. The objective ointments A, B, C, D and E for the radical cure of hemorrhoid and composed of varied amounts of the drug components can be obtained by this process. The amounts of the components are shown in the table I , wherein the number is weight (g) and the rightmost column is the ratio of zinc chloride in the whole preparation. The drugs A and B are used for the epithalaxia of dermatic membrane, e.g. archosyrinx, etc., C and D for the inner hemorrhoid, etc. and D and E for the dermatic part such as outer hemorrhoid, etc.